Introduction {#s1}
============

Breast cancer is the most common cancer and the leading cause of cancer death among women worldwide, accounting for 23% of the total cancer cases and 14% of the cancer deaths in 2008 [@pone.0069056-Jemal1]. The mechanism of breast carcinogenesis is still not fully understood. It has been suggested that environmental and genetic factors may affect the individual\'s susceptibility to cancer [@pone.0069056-Lichtenstein1]. High-penetrance breast cancer susceptibility genes, such as BRCA1 and BRCA2, explain only a small fraction of breast cancers in the general population because of their low mutation rates [@pone.0069056-Walsh1]. Over the past decades, the candidate approach has ever been successfully employed to identify BC susceptibility, such as ATM and XRCC1 of DNA repair genes have been confirmed to be associated with BC risk [@pone.0069056-Sun1]--[@pone.0069056-Liu1]. However, most of the genetic variants identified by candidate-gene studies have not been replicated [@pone.0069056-Zhang1]. Recently, several genome-wide association studies (GWAS) have been conducted and identified genetic susceptibility loci that are associated with breast cancer risk [@pone.0069056-Easton1]--[@pone.0069056-Thomas1]. The rs13387042 polymorphism at chromosome 2q35 has been identified as a new hotspot for breast cancer susceptibility by a recent GWA study [@pone.0069056-Stacey1]. Associations between the 2q35-rs13387042 polymorphism and breast cancer have been independently replicated by subsequent studies; however, a proportion of them have produced contrary results. Growing evidence suggests substantial heterogeneity by tumor subtype, defined by hormone receptor status, for association with the polymorphism [@pone.0069056-Hunter1], [@pone.0069056-Stacey1]. Because estrogen receptor (ER) and progesterone receptor (PR) statuses are the major markers of breast cancer subtypes, these observations suggest that inherited risk variants of these subtypes may vary. The lack of concordance across many of these studies reflects limitation in the studies, such as small sample size, ethnic difference, and study design. With the increased studies in recent years among East Asians, Africans and some other ethnic populations, there is a need to reconcile this inconsistency and to clarify the problems in previous studies. We therefore performed a meta-analysis of the published studies to clarify this inconsistency and to establish a comprehensive picture of the relationship between 2q35 rs13387042 polymorphism and breast cancer.

Materials and Methods {#s2}
=====================

Literature search strategy and inclusion criteria {#s2a}
-------------------------------------------------

Papers published before the end of January 2013 were identified through a search of Pubmed, SCOPUS, ISI web of knowledge, Embase and Cochrane databases Search term combinations were keywords relating to the chromosome 2q35 (e.g., "chromosome 2q35", and "rs13387042") in combination with words related to breast cancer (e.g., "breast cancer", "breast carcinoma", "malignant breast neoplasm") and polymorphism or variation. The titles and abstracts of potential articles were screened to determine their relevance, and any clearly irrelevant studies were excluded. The full texts of the remaining articles were read to determine whether they contained information on the topic of interest. In addition, all reference lists from the main reports and relevant reviews were hand searched for additional eligible studies not indexed by Medline.

Inclusion criteria and data extraction {#s2b}
--------------------------------------

Eligible studies had to meet all of the following criteria: (1) original papers containing independent data which have been published in peer-reviewed journal, (2) case--control or cohort studies, (3) genotype distribution information or odds ratio (OR) with its 95% confidence interval (CI) and *P*-value, (4) genotype distribution of control group must be consistent with Hardy--Weinberg equilibrium (HWE).

For each qualified study, the following information was extracted independently and entered into separate databases by two authors: first author\'s surname, publication date, ethnicity, source of control subjects, genotyping method, age, tumor stage, histopathological subtype, ER status, PR status, total number of cases and controls, and genotype frequency in cases and controls. The results were compared, and disagreements were discussed among all authors and resolved with consensus. For studies including subjects of different ethnic groups, data were extracted separately according to ethnicity. If multiple published reports from the same study population were available, we included only the one with largest sample size and the most detailed information. Meanwhile, different case--control groups in one study were considered as independent studies.

Statistical methods {#s2c}
-------------------

The meta-analysis examined the association between the rs13387042 polymorphism and the risk of BC, for the: (i) allele contrast, (ii) dominant, (iii) recessive, and (iv) co-dominant models [@pone.0069056-Palomaki1]. Crude ORs with 95% CIs were calculated using raw data, according to the method of Woolf B [@pone.0069056-Woolf1]. Cochran\'s Q-statistic test was performed to assess possible heterogeneity in the combined studies [@pone.0069056-Cochran1]. Both fixed-effects (Mantel--Haenszel method) [@pone.0069056-Mantel1] and random-effects (DerSimonian--Laird method) [@pone.0069056-DerSimonian1] models were performed to calculate the pooled ORs. Owing to a priori assumptions about the likelihood of heterogeneity between primary studies, the random-effects model, which usually is more conservative, was chosen. Sub-group analyses and meta-regression were used to explore heterogeneity [@pone.0069056-vanHouwelingen1]. Ethnicity, study design (GWAS vs. candidate gene study), ER status (ER-positive vs. ER-negative), PR status (PR-positive vs. PR-negative) and invasiveness (invasive vs. in situ) were prespecified as characteristics for assessment of heterogeneity. Ethnic group was defined as White (i.e., people of European origin), East Asian (e.g. Chinese, Japanese, and Korean), African and others (e.g., Jew and Hawaiian). One-way sensitivity analysis was performed to assess the stability of the results, namely, a single study in the meta-analysis was deleted each time to reflect the influence of the individual data set to the pooled OR. Funnel plots and the Egger\'s test were used to examine the influence of publication bias (linear regression analysis) [@pone.0069056-Egger1]. All P values are two-sided at the P = 0.05 level. All of the statistical tests used in this meta-analysis were performed by STATA version 10.0 (Stata Corporation, College Station, TX).

Results {#s3}
=======

Characteristics of included studies {#s3a}
-----------------------------------

The combined search yielded 113 references. 87 articles were excluded because they clearly did not meet the criteria or overlapping references ([Figure S1](#pone.0069056.s001){ref-type="supplementary-material"}). Finally, a total of 26 eligible association studies were included involving 101,529 breast cancer cases and 167,363 controls [@pone.0069056-Stacey1], [@pone.0069056-Milne1]--[@pone.0069056-Rinella1]. Of the cases, 80% were White, 12% were East Asian, 7% were African descent, and 1% were of other ethnic origins. The main study characteristics were summarized in [Table 1](#pone-0069056-t001){ref-type="table"}.

10.1371/journal.pone.0069056.t001

###### Characteristics of the studies included in the meta-analysis.

![](pone.0069056.t001){#pone-0069056-t001-1}

  Study                                              Year                    Ethnicity                       Genotyping method     No. of cases/controls   Control source   RAF in cases/controls    Study design
  ------------------------------------------------- ------ ---------------------------------------------- ----------------------- ----------------------- ---------------- ----------------------- ----------------
  Stacey [@pone.0069056-Stacey1]                     2008                     European                           SNP Array              4420/17365               GP               0.54/0.50              GWAS
  Milne [@pone.0069056-Milne1]                       2009                 European, Asian                    SNP Array, iPLEX           31511/35969            GP, HP             0.55/0.51              GWAS
  Zheng [@pone.0069056-Zheng2]                       2009                     African                            Massarray               810/1784                GP               0.77/0.74         Candidate gene
  Antoniou [@pone.0069056-Antoniou1]                 2009                European, American                    TaqMan, iPLEX             7805/6675               GP               0.53/0.51         Candidate gene
  Reeves [@pone.0069056-Reeves1]                     2010                     British                             TaqMan                10306/10393              GP               0.54/0.50         Candidate gene
  Hemminki [@pone.0069056-Hemminki1]                 2010                     European                             iPLEX                 1415/1830               GP               0.57/0.54         Candidate gene
  Zheng [@pone.0069056-Zheng3]                       2010                     Chinese                            SNP Array               3039/3082               GP               0.11/0.11         Candidate gene
  Barnholtz-Sloan [@pone.0069056-BarnholtzSloan1]    2010                     American                          GoldenGate               1230/1117               GP               0.55/0.53         Candidate gene
  Teraoka [@pone.0069056-Teraoka1]                   2011                European, American                     Golden Gate              704/1386                GP               0.55/0.52         Candidate gene
  Fletcher [@pone.0069056-Fletcher1]                 2011                     British                      SNP Array, GoldenGate         7643/7443               GP               0.53/0.52              GWAS
  Campa [@pone.0069056-Campa1]                       2011   American, European, African, Asian, Hawaiian     SNP Array, TaqMan          8314/11589               GP               0.52/0.49              GWAS
  Jiang [@pone.0069056-Jiang1]                       2011                     Chinese                            SNaPshot                 492/510                GP               0.12/0.10         Candidate gene
  Li [@pone.0069056-Li1]                             2011                     European                           SNP Array               1557/4584               GP               0.48/0.47         Candidate gene
  Chen [@pone.0069056-Chen1]                         2011                     African                            SNP Array               3016/2745               GP               0.73/0.72         Candidate gene
  Slattery [@pone.0069056-Slattery1]                 2011                     American                            TaqMan                 1733/2041               GP               0.53/0.52         Candidate gene
  Stevens [@pone.0069056-Stevens1]                   2011          European, American, Australian                  iPLEX                 2977/4976               GP               0.53/0.51         Candidate gene
  Hutter [@pone.0069056-Hutter1]                     2011                     African                            SNP Array               316/7484                GP               0.69/0.70         Candidate gene
  Dai [@pone.0069056-Dai1]                           2012                     Chinese                             TaqMan                 1771/1851               GP               0.13/0.11         Candidate gene
  He [@pone.0069056-He1]                             2012                     European                            TaqMan                3683/34174               GP               0.55/0.50         Candidate gene
  Shan [@pone.0069056-Shan1]                         2012                     Tunisian                            TaqMan                  640/367                GP               0.58/0.55         Candidate gene
  Kim [@pone.0069056-Kim1]                           2012                      Korean                        SNP Array, TaqMan           2257/2052               GP               0.10/0.10              GWAS
  Huo [@pone.0069056-Huo1]                           2012                     African                           GoldenGate               1509/1383               GP               0.77/0.75         Candidate gene
  Lin [@pone.0069056-Lin1]                           2012                     Chinese                            SNP Array                 88/69                 GP               0.15/0.06         Candidate gene
  Harlid [@pone.0069056-Harlid1]                     2012                     European                           MassARRAY               3393/4837               GP               0.53/0.50         Candidate gene
  Sueta [@pone.0069056-Sueta1]                       2012                     Japanese                            TaqMan                 697/1394                HP               0.10/0.10         Candidate gene
  Rinella [@pone.0069056-Rinella1]                   2013                      Jewish                             KASPar                  203/263                GP               0.66/0.52         Candidate gene

GP: general population, HP: hospital patient, RAF: risk allele frequency.

Association of 2q35-rs13387042 with breast cancer {#s3b}
-------------------------------------------------

There was a wide variation in the A allele frequency of the rs13387042 polymorphism among the controls across different ethnicities, ranging from 0.05 to 0.75 ([Table 1](#pone-0069056-t001){ref-type="table"}). For East Asian controls, the A allele frequency was 0.12 (95% CI: 0.08--0.16), which was lower than that in White controls (0.51; 95% CI: 0.48--0.53) and African controls (0.72; 95% CI: 0.65--0.79).

The main results of this meta-analysis were listed in [Table 2](#pone-0069056-t002){ref-type="table"} and [Table S1](#pone.0069056.s003){ref-type="supplementary-material"}. In the overall analysis, the rs13387042 polymorphism was significantly associated with elevated breast cancer risk with a per-allele OR of 1.14 \[95% CI: 1.11--1.16, P(Z)\<10^−5^, P(Q)\<10^−5^; [Figure 1](#pone-0069056-g001){ref-type="fig"}\], with corresponding results under dominant and recessive genetic models of 1.14 \[95% CI: 1.12--1.17, P(Z)\<10^−5^, P(Q) = 0.11\] and 1.17 \[95%CI: 1.13--1.21, P(Z)\<10^−5^, P(Q)\<10^−5^\]. Significant associations were also found for co-dominant genetic model \[heterozygous: OR = 1.15, 95% CI: 1.12--1.19, P(Z)\<10^−5^, P(Q)\<10^−4^; homozygous: OR = 1.20, 95% CI: 1.15--1.24, P(Z)\<10^−5^, P(Q)\<10^−5^\]. In the stratified analysis by ethnicity, significantly increased risks were found among East Asians \[A allele: OR = 1.12, 95% CI: 1.03--1.21, P(Z) = 0.004, P(Q) = 0.18; dominant model: OR = 1.10, 95% CI: 1.03--1.18, P(Z) = 0.003, P(Q) = 0.27; recessive model: OR = 1.09, 95% CI: 1.02--1.19, P(Z) = 0.01, P(Q) = 0.63; heterozygous: OR = 1.11, 95% CI: 1.04--1.20, P(Z) = 0.001, P(Q) = 0.33; homozygous: OR = 1.10, 95% CI: 1.02--1.19, P(Z)\<10^−4^, P(Q) = 0.25\] and White populations \[A allele: OR = 1.14, 95% CI: 1.12--1.17, P(Z)\<10^−5^, P(Q) = 0.02; dominant model: OR = 1.16, 95% CI: 1.13--1.18, P(Z)\<10^−5^, P(Q) = 0.59; recessive model: OR = 1.20, 95% CI: 1.14--1.24, P(Z)\<10^−5^, P(Q)\<10^−4^; heterozygous: OR = 1.15, 95% CI: 1.13--1.18, P(Z)\<10^−5^, P(Q) = 0.002; homozygous: OR = 1.21, 95% CI: 1.15--1.25, P(Z)\<10^−5^, P(Q)\<10^−4^\]. However, no significant associations were detected among African \[A allele: OR = 1.07, 95% CI: 0.99--1.16, P(Z) = 0.17, P(Q) = 0.03\] and other ethnic populations \[A allele: OR = 1.24, 95% CI: 0.59--2.61, P(Z) = 0.57, P(Q)\<10^−4^\]. Subsidiary analyses of study design yielded a per-allele OR for GWAS of 1.16 \[95% CI: 1.14--1.19, P(Q)\<10^−5^\] and for candidate gene study of 1.11 \[95% CI: 1.08--1.15, P(Q)\<10^−5^\].

![Forest plot from the meta-analysis of breast cancer risk and 2q35-rs13387042 polymorphism.](pone.0069056.g001){#pone-0069056-g001}

10.1371/journal.pone.0069056.t002

###### Meta-analysis of the 2q35-rs13387042 polymorphism on breast cancer risk.

![](pone.0069056.t002){#pone-0069056-t002-2}

  Sub-group analysis    No. of data sets   No. of cases/controls       A allele        Dominant model   Recessive model                                                                                                 
  -------------------- ------------------ ----------------------- ------------------- ---------------- ----------------- ------ ------------------- ---------- ------- ------ ------------------- ---------- ---------- ------
  Total                        44              101529/167363       1.14 (1.11--1.16)      \<10^−5^         \<10^−5^              1.14 (1.12--1.17)   \<10^−5^   0.11           1.17 (1.13--1.21)   \<10^−5^   \<10^−5^  
  Ethnicity                                                                                                               0.04                                          0.02                                             0.03
  White                        26              82814/140849        1.14 (1.12--1.17)      \<10^−5^           0.02                1.16 (1.13--1.18)   \<10^−5^   0.59           1.20 (1.14--1.24)   \<10^−5^   \<10^−4^  
  East Asian                   9                11681/11773        1.12 (1.03--1.21)       0.004             0.18                1.10 (1.03--1.18)    0.003     0.27           1.09 (1.02--1.19)     0.01       0.63    
  African                      7                6692/14193         1.07 (0.99--1.16)        0.07             0.13                1.07 (0.99--1.17)     0.09     0.12           1.06 (0.94--1.21)     0.37       0.22    
  Other                        2                  342/548          1.24 (0.59--2.61)        0.57           \<10^−4^              1.07 (0.66--1.76)     0.77     0.06           1.45 (0.89--2.09)     0.52      0.004    
  Study design                                                                                                            0.20                                          0.11                                             0.07
  GWAS                         5                54145/74418        1.16 (1.14--1.19)      \<10^−5^           0.38                1.16 (1.14--1.19)   \<10^−5^   0.25           1.18 (1.15--1.21)   \<10^−5^     0.16    
  Candidate gene               39               47384/92945        1.11 (1.08--1.15)      \<10^−5^           0.001               1.12 (1.09--1.16)   \<10^−5^   0.003          1.15 (1.11--1.19)   \<10^−5^   \<10^−4^  

Cochran\'s chi-square Q statistic test used to assess the heterogeneity in subgroups.

Cochran\'s chi-square Q statistic test used to assess the heterogeneity between subgroups.

We further performed analyses to test for differences in the associations of the polymorphism with breast cancer risk with respect to different prognostic factors. Specifically, we compared estrogen receptor--positive (ER+) case subjects with ER-negative (ER−) case subjects, and in a similar fashion progesterone receptor-positive (PR+) case subjects with receptor--negative (PR−) case subjects. Stratification of tumors by ER status indicated that rs13387042 had a stronger association with ER-positive \[per-allele OR = 1.17, 95% 1.15--1.19; P(Z)\<10^−5^; P(Q) = 0.47\] than ER-negative tumors \[per-allele OR = 1.08, 95% CI: 1.04--1.13; P(Z)\<10^−4^; P(Q) = 0.18\] ([Figure 2](#pone-0069056-g002){ref-type="fig"}). Similarly, a stronger association was also observed for the polymorphism with PR-positive tumors \[per-allele OR = 1.18, 95% CI: 1.15--1.21; P(Z)\<10^−5^; P(Q) = 0.57\] compared with PR-negative tumors \[per-allele OR = 1.10, 95% CI: 1.05--1.15; P(Z)\<10^−4^; P(Q) = 0.16\] ([Figure 3](#pone-0069056-g003){ref-type="fig"}).

![Association between 2q35-rs13387042 and breast cancer risk by ER status.](pone.0069056.g002){#pone-0069056-g002}

![Association between 2q35-rs13387042 and breast cancer risk by PR status.](pone.0069056.g003){#pone-0069056-g003}

The effect of the polymorphism was assessed for over-all breast cancer risk. No association was established between the polymorphism and tumor invasiveness. The data on tumor invasiveness were available in three studies, which included 20442 breast cancer patients. For 2q35-rs13387042, there appeared to be a similar per-allele OR for in situ cancer \[per-allele OR = 1.17, 95% CI: 1.04--1.13; P(Z)\<10^−5^; P(Q) = 0.27\] as compared to invasive cancer \[per-allele OR = 1.19, 95% CI: 1.15--1.22; P(Z)\<10^−5^; P(Q) = 0.51\].

Significant heterogeneity was present among the 44 data sets from 26 studies of the rs13387042 polymorphism (P\<0.05). In meta-regression analysis, sample size (P = 0.21), source of controls (P = 0.15) and genotyping method (P = 0.73) did not significantly explain such heterogeneity. By contrast, ethnicity (P = 0.004) was significantly correlated with the magnitude of the genetic effect.

Sensitivity analyses and publication bias {#s3c}
-----------------------------------------

Influence analysis was performed to assess the influence of each individual study on the pooled OR by sequential removal of individual studies. The results suggested that no individual study significantly affected the pooled OR, thus suggesting that the results of this meta-analysis are stable (data not shown). The shape of the funnel plot did not indicate any evidence of obvious asymmetry ([Figure S2](#pone.0069056.s002){ref-type="supplementary-material"}), thus suggesting no publication bias among the studies included. The statistical results still did not show preferential publication of positive findings in smaller studies (Begg\'s test, P = 0.27; Egger\'s test, P = 0.63).

Discussion {#s4}
==========

GWAS have led to the identification of multiple new genetic variants associated with breast cancer risk. Most of these breast cancer GWAS and replication studies have been conducted in European populations [@pone.0069056-Thomas1], [@pone.0069056-Stacey1], [@pone.0069056-Hemminki1], [@pone.0069056-Fletcher1] and to a lesser extent in East Asians [@pone.0069056-Zheng3], [@pone.0069056-Jiang1], [@pone.0069056-Dai1]. However, there are significant differences in allele frequencies and the prevalence of breast cancer among different populations. It is, therefore, important to quantitatively assess the effects of the GWAS-identified markers in different ethnic populations and explore potential heterogeneity of published data. To the best of our knowledge, this is the first comprehensive meta-analysis which comprises a total of 101,529 cases and 167,363 controls from 26 studies, examining the association of 2q35 rs13387042 polymorphism with breast cancer risk.

Our results demonstrated that the A allele of the 2q35-rs13387042 polymorphism is a risk factor for developing breast cancer. In the stratified analysis by ethnicity, significant associations were found in East Asians and Whites for the polymorphism in all genetic models. However, no significant associations were detected among African and other ethnic populations. There are some points should be concerned for such inconsistent results. Firstly, ethnic differences may attribute to these different results, since the distributions of the 2q35-rs13387042 polymorphism were different between various ethnic populations. For instance, the frequencies of risk-A allele differs from 6% in Chinese population [@pone.0069056-Lin1], 51% in Whites [@pone.0069056-Stacey1], [@pone.0069056-Reeves1], [@pone.0069056-Fletcher1], to 72% in African descents [@pone.0069056-Zheng2], [@pone.0069056-Chen1], [@pone.0069056-Hutter1]. On the other hand, a polymorphism may be in close linkage with another nearby causal variant in one ethnic population but not in another. 2q35-rs13387042 polymorphism may be in close linkage with different nearby causal variants in different populations. Furthermore, study design or small sample size or some environmental factors may affect the results. Most of these studies did not consider most of the important environmental factors. It is possible that variation at this locus has modest effects on breast cancer, but environmental factors may predominate in the progress of breast cancer, and mask the effects of this variation. Specific environmental factors like lifestyle and hormone replacement therapy that have been already well studied in recent decades [@pone.0069056-Lichtenstein1], [@pone.0069056-Parkin1]. The unconsidered factors mixed together may cover the role of 2q35-rs13387042 polymorphism. Thus, even if the variation has a causal effect on breast cancer, it may take a long time to be observed. Therefore, it is not surprising that inconsistent results for 2q35-rs13387042 polymorphism were found in breast cancer susceptibility.

The original publication on 2q35-rs13387042 [@pone.0069056-Stacey1] reported that the associated risk was confined to ER-positive breast cancer. We found that the association with rs13387042 was apparent for both ER-positive and ER-negative disease. However, the association appeared to be slightly stronger for ER-positive disease. This tendency to be more strongly associated with the risk of ER-positive breast cancer has been observed for other clearly established susceptibility SNPs, notably FGFR2-rs2981582, 8q-rs13281615, and 5p-rs10941679 [@pone.0069056-Stacey1], [@pone.0069056-GarciaClosas1], [@pone.0069056-Stacey2], perhaps reflecting the fact that they were initially identified by GWASs for which most of the case patients in the hypothesis-generating phases had ER-positive disease. In addition, we also found that the association appeared to be much stronger for PR-positive than the PR-negative breast cancer. It is unclear whether PR status has an effect on breast carcinogenesis independent of ER status. About 65% of ER-positive breast cancers are also PR-positive, and there is a high correlation between ER and PR expression [@pone.0069056-Nielsen1], [@pone.0069056-Yang1]. In addition, the per-allele odds ratio estimates were very similar for invasive and in situ disease.

A number of factors predict breast cancer, however, detailed pathogenesis mechanisms of breast cancer remain a matter of speculation. 2q35-rs13387042 is located in a 90-kb region of high linkage disequilibrium that contains neither known genes nor non coding RNAs [@pone.0069056-Stacey1], [@pone.0069056-Campa1]. The causal variant (or variants) in this region has (have) not been determined, and it is possible that one or more SNPs may confer a higher risk than 2q35-rs13387042. Thus, functional studies in this region are likely to lead to a better understanding of mechanisms of carcinogenesis and progression of breast cancer. However, the ORs we obtained were small with narrow CIs. This indicates that when considered alone as a genetic factor, the 2q35-rs13387042 polymorphism has a very small but detectable effect on susceptibility to breast cancer. This could be regarded simply as a weak genetic effect that has an additive effect when combined with other susceptibility loci.

Compared with the previous meta-analysis [@pone.0069056-Peng1], the present study is much larger, with almost sixty times as many cases as the earlier meta-analysis. In addition, we also performed analyses to test for differences in the associations of the polymorphism with breast cancer risk with respect to different hormone receptor status. Furthermore, we explored potential sources of heterogeneity across studies.

Limitations also inevitably existed in this meta-analysis. First, our meta-analysis is based on unadjusted estimates, whereas a more precise analysis could be performed if individual data were available, which would allow for an adjustment estimate. To be made, however, this approach requires the authors of all of the published studies to share their data. Second, no statistically significant association between the polymorphism and breast cancer appeared in other ethnic populations in racial subgroup analysis. However, the other ethnic population reports in the subgroup analysis include a mixture of populations from very distant countries, so the result must be interpreted with caution. Finally, the subgroup meta-analyses considering interactions between rs13387042 polymorphism and hormone receptor status, as well as tumor invasiveness were performed on the basis of a fraction of all the possible data to be pooled, so selection bias may have occurred and our results may be overinflated. Nevertheless, the total number of subjects included in this part of the analysis comprises the largest sample size so far.

Despite these limitations, this meta-analysis suggests that 2q35-rs13387042 polymorphism was significantly associated with increased risk of breast cancer, particularly in East Asian and white populations. As studies among other ethnic populations are currently limited, further studies including a wider spectrum of subjects to investigate the role of this variant in other populations will be needed.
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